4808 Results

People

  1. Travis
    Travis
  2. Berger
    Berger
  3. Hudis
    Hudis
  4. Ladanyi
    Ladanyi
  5. Arcila
    Arcila
  6. Reis-Filho
    Reis-Filho
  7. Weigelt
    Weigelt
  8. Giralt
    Giralt
  9. Levine
    Levine
  10. Motzer
    Motzer

Groups

  1. Department of Medicine (1855)
  2. GSK Faculty (1116)
  3. Solid Tumor Oncology Division (1035)
  4. Surgery (883)
  5. Survivorship Research (752)
  6. Center for Hematologic Malignancies (746)
  7. Department of Pathology and Laboratory Medicine (714)
  8. Hematologic Malignancies, Division of (683)
  9. Population Sciences Research Program (601)
  10. Sloan Kettering Institute Faculty (586)
  1. "2015"
Formats
  1. Journal Article (2716)
  2. Meeting Abstract (1680)
  3. Book Section (364)
  4. Conference Paper (26)
  5. Book Whole (19)
  6. Review (2)
  7. Research Letter (1)
Groups
  1. Department of Medicine (1855)
  2. GSK Faculty (1116)
  3. Solid Tumor Oncology Division (1035)
  4. Surgery (883)
  5. Survivorship Research (752)
  6. Center for Hematologic Malignancies (746)

More Groups

People
  1. William Travis (102)
  2. Michael Berger (96)
  3. Clifford Hudis (85)
  4. Marc Ladanyi (79)
  5. Jedd Wolchok (68)
  6. Britta Weigelt (67)

More People

Years
  1. 2015 (4808)
Publications
  1. Journal of Clinical Oncology (475)
  2. Blood (224)
  3. Cancer Research (168)
  4. Modern Pathology (125)
  5. Laboratory Investigation (112)
  6. International Journal of Radiation Oncology, Biology, Physics (91)

More Publications

Publishers
  1. Elsevier Inc. (581)
  2. American Society of Clinical Oncology (508)
  3. Springer (380)
  4. Nature Publishing Group (301)
  5. American Association for Cancer Research (263)
  6. American Society of Hematology (228)

More Publishers

Results (4808)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Heavy light chain ratio normalization allows identification of electrophoretic non-complete response patients with improved outcomes: A long term follow up update for BMT CTN 0102 correlative study
    Meeting Abstract

    D'Souza, A.; Pasquini, M.; Logan, B.; Giralt, S.; Krishnan, A.; Antin, J.; Howard, A.; Horowitz, M.; Goodman, S.; Laport, G.; more...
    Haematologica (2015)

    Fulltext@MSK | Save
  • A prior cancer diagnosis is not a risk factor for the developement of subsequent cancers in multiple myeloma patients
    Meeting Abstract

    Jonsdottir, G.; Lund, S. H.; Bjorkholm, M.; Hultcrantz, M.; Landgren, O.; Kristinsson, S. Y.
    Haematologica (2015)

    Fulltext@MSK | Save
  • Cardiovascular (CV) and pulmonary adverse events (AES) in patients (PTS) treated with BCR-ABL tyrosine kinase inhibitors (TKIS): Updated analysis from the FDA Adverse Event Reporting System (FAERS)
    Meeting Abstract

    Cortes, J.; Mauro, M.; Steegmann, J. L.; Saglio, G.; Soitkar, A.; Wallis, N.
    Haematologica (2015)

    Fulltext@MSK | Save
  • Safety of idelalisib in B-cell malignancies: Integrated analysis of eight clinical trials
    Meeting Abstract

    Coutre, S.; Barrientos, J.; Brown, J.; de Vos, S.; Furman, R.; Keating, M.; O'Brien, S.; Pagel, J.; Sharman, J.; Zelenetz, A.; more...
    Haematologica (2015)

    Fulltext@MSK | Save
  • Ag-221, an oral, selective, first-in-class, potent inhibitor of the IDH2 mutant enzyme, induced durable responses in a phase 1 study of IDH2 mutation-positive advanced hematologic malignancies
    Meeting Abstract

    DiNardo, C.; Stein, E. M.; Altman, J. K.; Collins, R.; DeAngelo, D. J.; Fathi, A. T.; Flinn, I.; Frankel, A.; Levine, R. L.; Medeiros, B. C.; more...
    Haematologica (2015)

    Fulltext@MSK | Save
  • Clinical safety and activity of AG-120, a first-in-class, potent inhibitor of the IDH1 mutant protein, in a phase 1 study of patients with advanced IDH1-mutant hematologic malignancies
    Meeting Abstract

    de Botton, S.; Pollyea, D. A.; Stein, E. M.; DiNardo, C.; Fathi, A. T.; Roboz, G. J.; Collins, R.; Swords, R. T.; Flinn, I.; Altman, J. K.; more...
    Haematologica (2015)

    Fulltext@MSK | Save
  • DNMT3A R882 mutation promote chemoresistance and therapeutic relapse through impaired DNA-damage sensing
    Meeting Abstract

    Guryanova, O.; Shank, K.; Garrett-Bakelman, F.; Spitzer, B.; Ganzel, C.; Rapaport, F.; Keller, M.; Evangelista, L.; Glass, J.; Rowe, J.; more...
    Haematologica (2015)

    Fulltext@MSK | Save
  • BCl6 and EZH2 cooperate to assemble non-canonical PRC1-BCOR complex to mediate germinal center formation and promote lymphomagenesis by repressing bivalent chromatin domains
    Meeting Abstract

    Béguelin, W.; Teater, M.; Hatzi, K.; Jiang, Y.; Gascoyne, R. D.; Abdel-Wahab, O.; Shaknovich, R.; Bardwell, V. J.; Elemento, O.; Melnick, A. M.
    Haematologica (2015)

    Fulltext@MSK | Save
  • Outcomes of allogeneic hematopoietic cell transplantation (HCT) in patients with myelofibrosis (MF) exposed to JAK1/2 inhibitors
    Meeting Abstract

    Shanavas, M.; Popat, U.; Michaelis, L. C.; Fauble, V.; McLornan, D.; Klisovic, R.; Mascarenhas, J.; Tamari, R.; Arcasoy, M.; Davies, J.; more...
    Haematologica (2015)

    Fulltext@MSK | Save
  • A phase 1 trial of CUDC-907, an oral, first-in-class, dual inhibitor of HDAC and PI3K, in patients with refractory or relapsed lymphoma and multiple myeloma
    Meeting Abstract

    Oki, Y.; Berdeja, J.; Patel, M.; Flinn, I.; Gerecitano, J.; Neelapu, S.; Copeland, A.; Akins, A.; Clancy, M.; Viner, J.; more...
    Haematologica (2015)

    Fulltext@MSK | Save